Replies to post #9199 on Cosciens Biopharma Inc (CSCIF)

[MinnieM]

A pre-specified second interim efficacy and safety analysis of the compound will be completed in early October 2015. Phase three trial results won't be ready at that time, but, we'll find out whether or not the trial will continue.


http://finance.yahoo.com/news/aeterna-zentaris-announces-data-safety-113000737.html

QUEBEC CITY, Aug. 11, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (AEZS) (AEZ.TO) (the "Company") today announced that the independent Data and Safety Monitoring Board ("DSMB") for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.

If the trial is continued the listed completion date is in 2016.

https://clinicaltrials.gov/ct2/show/NCT01767155?term=aeterna+endometrial&rank=1

Estimated Enrollment: 500
Study Start Date: April 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)

In Reply to 'rlangmaid'
Do we have a date in October?